The current financial score of ANI Pharmaceuticals Inc is 9.11. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 290.78M, representing a year-over-year increase of 27.64%, while its net profit experienced a year-over-year increase of 47.75%.
The current valuation score of ANI Pharmaceuticals Inc is 8.58. Its current P/E ratio is 16.39, which is 620.35% below the recent high of 118.04 and 981.65% above the recent low of -144.47.
The current earnings forecast score of ANI Pharmaceuticals Inc is 8.22. The average price target is 104.62, with a high of 121.00 and a low of 85.00.
The current price momentum score of ANI Pharmaceuticals Inc is 2.99. Currently, the stock price is trading between the resistance level at 73.22 and the support level at 64.39, making it suitable for range-bound swing trading.
The current institutional shareholding score of ANI Pharmaceuticals Inc is 10.00. The latest institutional shareholding proportion is 101.74%, representing a quarter-over-quarter increase of 1.25%.
The current risk assessment score of ANI Pharmaceuticals Inc is 8.10. The company's beta value is 0.45. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.